ClinicalTrials.gg

Program

TRL1068

Also written as “TRL1068, a human monoclonal antibody”.

Its studies are mostly in Nasal Polyps, led by Trellis Bioscience.

Furthest: phase 1, since Feb 12, 20213 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Trellis Bioscience31 open or runningphase 1since Feb 12, 2021Feb 12, 2021Dec 2026phase 1 · NCT07644195

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2021First study: phase 1 study in Prosthetic Joint InfectionFirst studyNCT04763759 · 15 enrolled · United States
  2. Apr 18, 2022Phase 1 study in Chronic Rhinosinusitis With Nasal PolypsNCT05355207 · 12 enrolled
  3. Jun 8, 2026Phase 1 study in Healthy VolunteerNCT07644195 · 14 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 1 study in Healthy VolunteerNCT07644195

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07644195Healthy Volunteer · United States1Not yet recruitingDec 202614
NCT05355207Chronic Rhinosinusitis With Nasal Polyps1UNKNOWNJan 202512
NCT04763759Prosthetic Joint Infection · United States1CompletedMar 13, 202415

How it is read

Names in the registry

  • “TRL1068, a human monoclonal antibody”, 2 entries
  • “TRL1068”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.